Maze Therapeutics SVP Finance Amy Bachrodt to resign effective June 1, 2026

Maze Therapeutics, Inc.

Amy Bachrodt resigns as SVP, Finance, effective June 1, 2026.
Resignation not related to any disagreement with the company.
CFO Misbah Tahir will assume principal accounting officer role.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-237199
form_type: 8-K
ticker: MAZE
cik: 0001842295
company_name: Maze Therapeutics, Inc.
filed_at: 2026-05-22T21:24:41+00:00
discovered_at: 2026-05-22T21:26:00.257527+00:00
generated_at: 2026-05-22T21:28:16.063597+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-237199
json_url: https://secwatch.observer/filing/0001193125-26-237199.json
markdown_url: https://secwatch.observer/filing/0001193125-26-237199.md
text_url: https://secwatch.observer/filing/0001193125-26-237199.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/d909749d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Misbah Tahir

Chief Financial Officer and principal accounting officer

MAZE · Maze Therapeutics, Inc.

Effective: 2026-06-01
Filed: May 22, 2026 21:24 UTC

Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.

Departed

Amy Bachrodt

Senior Vice President, Finance

MAZE · Maze Therapeutics, Inc.

Effective: 2026-06-01
Successor: Misbah Tahir
Filed: May 22, 2026 21:24 UTC

On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.

Source-grounded claims

1bd3306082

Misbah Tahir changed role as Chief Financial Officer and principal accounting officer at Maze Therapeutics, Inc..

Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.

SEC 8-K Item 5.02 confidence 0.9 SEC evidence

c95279582e

Amy Bachrodt departed as Senior Vice President, Finance at Maze Therapeutics, Inc..

On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR

accession 0001193125-26-237199

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.